JP2014518871A - ２つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム - Google Patents

２つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム Download PDF

Info

Publication number
JP2014518871A
JP2014518871A JP2014511329A JP2014511329A JP2014518871A JP 2014518871 A JP2014518871 A JP 2014518871A JP 2014511329 A JP2014511329 A JP 2014511329A JP 2014511329 A JP2014511329 A JP 2014511329A JP 2014518871 A JP2014518871 A JP 2014518871A
Authority
JP
Japan
Prior art keywords
suspension
active agent
particles
less
fev
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511329A
Other languages
English (en)
Japanese (ja)
Inventor
ヴェリング，レインハード
スティーブン ハートマン，マイケル
レチュガ−バレステロス，デーヴィッド
エドワード スミス，エイドリアン
ビー． ジョシ，ヴィドヤ
クマール ドウィヴェディ，サルヴァニャ
Original Assignee
パール セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パール セラピューティクス，インコーポレイテッド filed Critical パール セラピューティクス，インコーポレイテッド
Publication of JP2014518871A publication Critical patent/JP2014518871A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/02—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014511329A 2011-05-17 2011-05-17 ２つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム Pending JP2014518871A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/036868 WO2012158166A1 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (1)

Publication Number Publication Date
JP2014518871A true JP2014518871A (ja) 2014-08-07

Family

ID=47177229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511329A Pending JP2014518871A (ja) 2011-05-17 2011-05-17 ２つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム

Country Status (13)

Country Link
EP (1) EP2709447A4 (pt)
JP (1) JP2014518871A (pt)
KR (1) KR20140032404A (pt)
CN (1) CN103687483A (pt)
AU (1) AU2011368334A1 (pt)
BR (1) BR112013029507A2 (pt)
CA (1) CA2835927A1 (pt)
EA (1) EA201490991A1 (pt)
IL (1) IL229260A0 (pt)
MX (1) MX2013013440A (pt)
RU (1) RU2013155903A (pt)
SG (1) SG194896A1 (pt)
WO (1) WO2012158166A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI695723B (zh) 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
SG11201505556VA (en) 2013-01-31 2015-08-28 Prosonix Ltd Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
JP2016519160A (ja) * 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
CN111150728B (zh) 2013-12-30 2024-02-06 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
NO3096737T3 (pt) * 2013-12-30 2018-09-01
BR112017003888B1 (pt) 2014-09-09 2022-11-16 Vectura Limited Método de fabricação de uma formulação de pó seco
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
CN105125542A (zh) * 2015-08-23 2015-12-09 杭州紫金医药科技有限公司 含噻托溴铵和福莫特罗的药物组合物及其用途和制剂
CN106880636A (zh) * 2015-12-15 2017-06-23 天津金耀集团有限公司 一种环索奈德单方和复方干粉吸入剂组合物
CN106880637B (zh) * 2015-12-15 2021-01-29 天津金耀集团有限公司 一种环索奈德福莫特罗噻托溴铵复方干粉吸入剂组合物
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
US20210393598A1 (en) * 2018-11-12 2021-12-23 Kindeva Drug Delivery L.P. Umeclidinium and vilanterol formulation and inhaler
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
TW202241410A (zh) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 可經由定量吸入器遞送的藥物組合物
KR20240042438A (ko) * 2021-07-09 2024-04-02 아스트라제네카 파마수티컬스 엘피 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525842A (ja) * 1997-09-29 2003-09-02 インヘール セラピューティック システムズ， インコーポレイテッド 計量吸入器における使用のための安定化調製物
JP2007520506A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
WO2010138884A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525842A (ja) * 1997-09-29 2003-09-02 インヘール セラピューティック システムズ， インコーポレイテッド 計量吸入器における使用のための安定化調製物
JP2007520506A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
WO2010138884A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
WO2010138868A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems

Also Published As

Publication number Publication date
WO2012158166A1 (en) 2012-11-22
CA2835927A1 (en) 2012-11-22
EP2709447A4 (en) 2014-10-22
IL229260A0 (en) 2014-01-30
KR20140032404A (ko) 2014-03-14
RU2013155903A (ru) 2015-06-27
CN103687483A (zh) 2014-03-26
EA201490991A1 (ru) 2014-09-30
BR112013029507A2 (pt) 2019-09-24
SG194896A1 (en) 2013-12-30
EP2709447A1 (en) 2014-03-26
MX2013013440A (es) 2014-06-05
AU2011368334A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
JP6348645B2 (ja) ２つ以上の活性剤を呼吸器送達するための組成物、方法および系
US20240024229A1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
JP2014518871A (ja) ２つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム
AU2020210160B2 (en) Compositions, methods & systems for respiratory delivery of two or more active agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027